Alzheimer's Tau Platform: Master Protocol

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

750

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Preclinical Alzheimer's DiseaseAlzheimer DiseaseProdromal Alzheimer's Disease
Interventions
DRUG

AADvac1

AADvac1 tau directed therapy

DRUG

Tau2

Tau2 directed therapy

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

University of California, San Francisco

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Alzheimer's Therapeutic Research Institute

OTHER

collaborator

Alzheimer's Clinical Trials Consortium

OTHER

lead

Paul S. Aisen

OTHER